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Introduction: Obesity and colorectal cancer could be linked by adipocytokines, which are 
proteins associated with cell proliferation. High levels of the adipocytokine leptin promote 
the development of colorectal cancer through its receptor. 
Objective: To determine the association between c.326A>G and c.668A>G LEPR gene 
polymorphisms and colorectal cancer.
Materials and methods: DNA was extracted from the peripheral blood of 147 patients with 
sporadic colorectal cancer and 134 healthy people. Genotypes were obtained by PCR-
RFLP and the association was determined by the odds ratio (OR) test using the SPSS™, 
version 10.0, program. Haplotype frequencies and linkage disequilibrium were estimated by 
the Arlequin, version 3.5, software. 
Results: Both polymorphisms were in Hardy-Weinberg equilibrium. Only the c.326A>G 
heterozygous genotype revealed an increased risk for colorectal cancer development 
(OR=1.81, 95% CI=1.04-3.16, p=0.04). The AG haplotype showed a significant association 
with colorectal cancer (OR=0.58, 95% CI=0.35-0.96, p<0.03). Linkage disequilibrium 
between the variants was only evident for the patients group (r2=0.36). 
Conclusion: Our results suggest that AG individuals heterozygous for the c.326A>G 
LEPR variant have a higher risk of colorectal cancer development whereas the AG 
haplotype (c.326A/c.668G) has a protective effect in the Mexican population.
Key words: Receptors, leptin; colorectal neoplasms; polymorphism, genetic; haplotypes; 
odds ratio; Mexico.
Polimorfismos y haplotipos del gen LEPR en pacientes mexicanos con cáncer 
colorrectal
Introducción. La relación entre la obesidad y el cáncer colorrectal podría estar dada por las 
adipocitocinas, proteínas asociadas con la proliferación celular. Los niveles elevados de la 
adipocitocina leptina promueven el desarrollo del cáncer colorrectal a través de su receptor.
Objetivo. Determinar la asociación de los polimorfismos c.326A>G y c.668A>G del gen 
LEPR con el cáncer colorrectal.
Materiales y métodos. A partir de sangre periférica, se extrajo el ADN de 147 pacientes 
con cáncer colorrectal esporádico y de 134 personas sanas. La genotipificación se hizo 
mediante PCR-RFLP y la asociación se determinó por la odds ratio (OR) en el programa 
SPSS™, versión 10.0. Las frecuencias haplotípicas y el desequilibrio de ligamiento se 
estimaron utilizando el programa Arlequin, versión 3.5.
Resultados. Ambos polimorfismos estaban en equilibrio de Hardy-Weinberg. Solo el 
genotipo heterocigoto c.326A>G reveló un mayor riesgo de desarrollar cáncer colorrectal 
(OR=1,81; IC95% 1,04-3,16; p=0,04). El haplotipo AG mostró una asociación significativa 
con este cáncer (OR=0,58; IC95% 0,35-0,96; p≤0,03) y el desequilibrio de ligamiento entre 
las variantes fue evidente únicamente en el grupo de pacientes (r2=0,36). 
Conclusión. Los resultados sugieren que los individuos heterocigotos con el haplotipo AG para 
la variante c.326A>G en el gen LEPR tenían un mayor riesgo de desarrollar cáncer colorrectal, 
en tanto que el haplotipo AG (c.326A/c.668G) tenía un efecto protector en la población mexicana.
Palabras clave: receptores de leptina; neoplasias colorrectales; polimorfismo genético; 
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Colorectal cancer is the second (in women) or third (in men) most common 
neoplasm worldwide. In México, colorectal cancer ranks fourth in both sexes 
(1). Environmental, genetic and epigenetic factors have been related to 
colorectal cancer development (2-4). Although obesity increases the risk of 
colorectal cancer by 1.5- to 2-fold (5) and 17.7% of the cases are ascribed to 
excess body mass (6), the cause of this association is not yet clear.
The relationship between colorectal cancer and obesity may reflect the 
impaired structure or function of adipocytokines, which are proteins that 
regulate cell proliferation, angiogenesis, and apoptosis (7). For instance, an 
increase in leptin appears to promote the development and progression of 
colorectal cancer (8). 
The LEPR (leptin receptor) protein is encoded by a gene in the 1p31.3 
locus (9). The LEPR polymorphisms c.326A>G (rs1137100) and c.668A>G 
(rs1137101) are located in exons 4 and 6, respectively. The former results 
in a conservative substitution of arginine for lysine in codon 109 (p.K109R) 
while the latter produces a non-conservative change of glutamine to arginine 
in codon 223 (p.Q223R) (10). This p.Q223R substitution occurs inside the 
region coding for the extracellular domain and could affect the interaction with 
leptin (11). Even if the impact of the LEPR pathway in C colorectal cancer 
is not yet clear, increased expression in tumor tissue has been related to 
proliferation and angiogenesis (12). 
The objective of this study was to determine the association between 




The analysis included 147 patients diagnosed by histopathological 
and clinical criteria with sporadic colorectal cancer at the Hospital Civil de 
Guadalajara “Dr. Juan I. Menchaca”. The group included 87 males and 60 
females with an average age of 57 years (range: 20 to 69 years). The control 
group was integrated by 134 blood donors from the same hospital without a 
colorectal cancer diagnosis. 
All subjects signed the informed consent. This study was approved by 
the ethics committee of Centro Universitario de Los Altos, Universidad de 
Guadalajara (CUA/CINV/PCIL-011/2009).
DNA extraction
We used the Miller method (13) combined with the DTAB-CTAB 
protocol (14) on each 5-ml sample of peripheral blood with EDTA added 
as an anticoagulant. DNA purity and concentration were determined by 
spectrophotometry.
PCR-RFLP
We searched for LEPR variants with a PCR-RFLP protocol 
according to predetermined conditions (15,16). For the c.326A>G 
variant, we used 5’-TTTCCACTGTTGCTTTCGGA-3’ forward and 
5’-AAACTAAAGAATTTACTGTTGAAACAAATGGC-3’ reverse primers 
under the following conditions: DNA initial denaturation for 5 min at 94°C; 40 
207
Biomédica 2019;39:205-11 LEPR variants in colorectal cancer
cycles of 94°C for 45 s, annealing at 61.8°C for 45 s, extension at 72°C for 
90s, and a final extension at 72°C for 10 min. We looked for the c.668A>G 
LEPR polymorphism using 5’-AAACTCAACGACACTCTCCTT–3’ forward 
and 5’-TGAACTGACATTAGAGGTGA-3’ reverse primers and amplification 
conditions similar to those described above except for an annealing 
temperature of 55°C. 
For the single nucleotide polymorphism analysis, we used the restriction 
enzymes HaeIII for c.326A>G and HpaII for c.668A>G (both of which 
recognize the polymorphic G allele) for 16 hours. The assays were done in 
duplicate.
Electrophoresis
DNA fragments were identified in 6% polyacrylamide gels stained with 
silver nitrate. Their sizes were 101, 70 and 31 bp for c.326A>G and 80, 58 
and 22 bp for c.668A>G.
Statistical analysis
Allelic and genotypic frequencies were determined by direct counting. The 
distribution of genotypes was tested for Hardy-Weinberg equilibrium using 
the c2 test. Haplotype frequencies and linkage disequilibrium values were 
calculated by the Arlequin, version 3.5, software (17). Linkage disequilibrium 
with r2>0.3 was considered to be significant (18). Intergroup differences were 
established by c2 or Fisher’s exact test and the association was determined 
by the odds ratio (OR) in SPSS™, version 10.0.
Results
LEPR polymorphisms
Demographic and clinical data of CRC patients are listed in table 1. In the 
control group, both LEPR polymorphisms were in Hardy-Weinberg equilibrium 
(p>0.05). For methodological reasons, not all individuals were included in the 
analysis. The comparison between controls and colorectal cancer patients 
associated the AG genotype of c.326A>G to an increased risk for colorectal 
cancer (OR=1.81, 95% CI=1.04-3.16, p=0.04) while no association was 
found for the c.668A>G polymorphism (table 2).
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LEPR haplotypes
The haplotype AA was the most frequent in controls (93/194; 48%) and 
colorectal cancer patients (132/254; 52%). LD was only evident among the 
latter (r2=0.36). The AG haplotype showed a significant association with 
colorectal cancer (OR=0.58, CI=0.35-0.96, p<0.03) (table 3).
Table 2. Genotypes and allele frequencies of c.326 A>G and c.668A>G LEPR polymorphisms in 
controls and colorectal cancer patients
Table 3. Haplotype frequencies for c.326 A>G/c.668 A>G LEPR polymorphisms
CRC: Colorectal cancer; OR: Odds ratio; CI: Confidence interval.
*Chi-square or Fisher´s exact test; figure in bold corresponds to p<0.05
CRC: Colorectal cancer; OR: Odds ratio; CI: Confidence interval
*Chi-square or Fisher´s exact test; figure in bold corresponds to p<0.05
Gene LEPR
SNP c.326 A>G
Control (N=100) CRC (N=127)
OR (95% CI) p*












































































p*Control (N=100) CRC (N=127)





























Our finding of an increased risk of colorectal cancer in heterozygous 
AG individuals for the LEPR c.326A>G polymorphism compares with a 
similar association documented in Korean patients with gastric cancer (19). 
Regarding the same single nucleotide polymorphism (SNP), an increased 
risk (OR=1.64; 95%CI=1.10-2.45; p=0.016) for luminal A breast cancer was 
observed in GG patients (20) whereas the G allele was associated with 
prostate cancer mortality (hazard ratio=0.82: 95%CI=0.67-1.00; p=0.027) in 
another study (21). Moreover, this missense c.326A>G (p.K109R) variant was 
associated with increased birth weight in the Human Gene Mutation Database 
(HGMD-public: CM032948) (22). However, no association was found in other 
cancer studies (16,23,24).
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Inasmuch as lysine (K) and arginine (R) are basic large-size amino acids 
(25), the Ensembl project― as predicted by SIFT and Polyphen― classified 
this variant as tolerable and benign (26). Yet, the higher propensity of lysine 
to post- translation modifications (methylation, ubiquitination, acetylation, 
phosphorylation, and sumoylation) indicates that its substitution could lead to 
protein structure alterations and increase colorectal cancer susceptibility (27). 
The lack of association of the LEPR c.668A>G polymorphism with 
colorectal cancer in this and previous studies (11,28-31), and also 
documented in other neoplasms (16,23,32-37), probably reflects that the 
change of glutamine (Q), a polar amino acid of medium size, to arginine (R), 
a large-sized and basic amino acid, is harmless. 
However, opposite results have been reported. In Caucasian women with 
breast cancer, the G allele was related to differentiation grade (OR=2.45, 
95%CI 1.40–4.31) (38). Likewise, an increased risk for breast (39), oral (40), 
and lung (41) cancer development ascribed to the same variant has been 
proposed. Additionally, two meta-analyses revealed no association with cancer 
(42,43). These controversial results could be explained by the genetic structure 
of populations or the presence of additional variants modifying the LEPR gene.
The apparent protective effect of the AG haplotype disclosed in the 
present analysis (c.326A>G/c.668A>G) is consistent with the view that the 
accumulation of LEPR variants and gene interactions modulates colorectal 
cancer risk and development.
In conclusion, our results indicate that in the Mexican population, the AG 
genotype of the c.326A>G LEPR variant increases the risk of CRC, whereas 
the AG haplotype (c.326A/c.668G) protects against such tumors.
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